Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo de SM04554 aplicado topicamente ao couro cabeludo de indivíduos do sexo masculino com alopecia androgenética analisado por biópsia do couro cabeludo antes e após a dosagem

9 de setembro de 2026 atualizado por: Biosplice Therapeutics, Inc.

Um estudo de fase 2, multicêntrico, randomizado, duplo-cego de SM04554 aplicado topicamente ao couro cabeludo de indivíduos do sexo masculino com alopecia androgenética (AGA) analisado por biópsia do couro cabeludo antes e após a dosagem

This study will assess the safety, tolerability, and efficacy of SM04554 at concentrations of 0.15% and 0.25%. Improved knowledge of the changes in hair counts and immunohistochemical analysis associated with androgenetic alopecia (AGA) before and after treatment with SM04554 and compared to placebo may lead to a greater understanding of the underlying mechanisms of action of SM04554.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Real)

49

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Michigan
      • Clinton Township, Michigan, Estados Unidos
        • Research Site
    • Ohio
      • Cleveland, Ohio, Estados Unidos
        • Research Site
    • Texas
      • College Station, Texas, Estados Unidos
        • Research Site
      • Houston, Texas, Estados Unidos
        • Research Site
    • Virginia
      • Lynchburg, Virginia, Estados Unidos
        • Research Site

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 65 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Macho

Descrição

Inclusion Criteria:

  • Clinical diagnosis of AGA with Norwood-Hamilton Classification score of 4, 5, 5A, 5V, or 6
  • In good general health, as determined by the Investigator
  • Willing and able to attend all study visits
  • Willing to undergo two punch biopsies of the scalp
  • Willing to inform females, with whom they may interact, that they are using a topical investigational product and direct contact should be avoided as potential harm to a fetus is unknown
  • Willing to not use permanent or semi-permanent hair products (e.g., color, texturizers, relaxers) for the duration of the study; daily styling products will be allowed on non-study visit days (e.g., hair gel, mousse, styling spray)
  • Willing to use sponsor-supplied shampoo and conditioner in place of regular shampoo and conditioner, for the duration of the study; use of sponsor-supplied conditioner is optional for subjects who do not use conditioner

Exclusion Criteria:

  • Clinical diagnosis of alopecia areata or other non-AGA forms of alopecia
  • Scalp hair loss on the treatment area, due to disease, injury, or medical therapy
  • Males who are sexually active and have a partner who is capable of becoming pregnant, neither of whom have had surgery to become sterilized, that are not using a highly effective method of birth control and are not willing to use a highly effective method of birth control during the study treatment period until 90 days post last dose of study medication
  • Current skin disease (e.g., psoriasis, atopic dermatitis, eczema, sun damage, seborrheic dermatitis, actinic keratosis), cuts and/or abrasions on the scalp or hands or condition (e.g., sunburn, tattoos) on the treatment area or hands that, in the opinion of the Investigator, might put the subject at risk or interfere with the study conduct or evaluations
  • History of or current skin cancer (e.g., melanoma, basal cell carcinoma, squamous cell carcinoma) located anywhere on the body
  • History of surgical correction of hair loss on the scalp
  • Previous exposure to SM04554
  • Use of blood thinners (e.g., Coumadin, Plavix, Lovenox, and aspirin >81mg); low dose aspirin (e.g., ≤81 mg) is allowable
  • Use of any products or devices clinically proven to promote scalp hair growth (e.g., finasteride or minoxidil) within 24 weeks prior to study start
  • Use of anti-androgenic therapies (e.g., spironolactone, flutamide, cyproterone acetate, cimetidine) within 12 weeks prior to study start
  • Use of semi-permanent hair products (e.g., color, texturizers, relaxers) within 30 days prior to study start
  • Use of medicated shampoo or conditioner (medicated shampoo and conditioner refer to any prescription shampoo or conditioner as well as any over-the-counter medicated shampoo or conditioner, such as those for treatment of dandruff or promoting hair growth) within 30 days prior to study start
  • History of hair transplants
  • Current use of an occlusive wig, hair extensions, or hair weaves
  • Participation in any other investigational drug or medical device trial which included administration of an investigational study medication or medical device, within 30 days or 5 half-lives of the investigational agent, whichever is longer, prior to study start
  • Poor peripheral venous access
  • Subjects unwilling to refrain from sperm donation during the study treatment period until 90 days post last dose of study medication
  • Subjects with pregnant partners at study start
  • Subjects who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study at the investigative site, or are directly affiliated with the study at the investigative site
  • Subjects employed by Samumed, LLC, or any of its affiliates or development partners (that is, an employee, temporary contract worker, or designee) responsible for the conduct of the study

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Triplo

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Topical SM04554 0.15% solution

Topical SM04554 0.15% solution, once daily for approximately 90 days

Study medication application will be performed by the individual subject at approximately the same time each day.

Experimental: Topical SM04554 0.25% solution

Topical SM04554 0.25% solution, once daily for approximately 90 days

Study medication application will be performed by the individual subject at approximately the same time each day.

Comparador de Placebo: Vehicle

Topical vehicle solution, once daily for approximately 90 days

Vehicle solution application will be performed by the individual subject at approximately the same time each day.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change From Baseline/Day 91 in Number of Terminal Hair Follicles (Terminal Anagen + Terminal Catagen and Telogen Follicles)
Prazo: Day 91 and Day 135

Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.

Day 91 and Day 135
Change From Baseline/Day 91 in Number of Terminal Anagen Hair Follicles
Prazo: Day 91 and Day 135

Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.

Day 91 and Day 135
Change From Baseline/Day 91 in Number of Terminal Catagen and Telogen Hair Follicles
Prazo: Day 91 and Day 135

Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.

Day 91 and Day 135
Change From Baseline/Day 91 in Number of Miniaturized Hair Follicles (Indeterminate + Vellus Follicles)
Prazo: Day 91 and Day 135

Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.

Day 91 and Day 135
Change From Baseline/Day 91 in Number of Indeterminate Hair Follicles
Prazo: Day 91 and Day 135

Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.

Day 91 and Day 135
Change From Baseline/Day 91 in Number of Vellus Hair Follicles
Prazo: Day 91 and Day 135

Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.

Day 91 and Day 135

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Terminal and Miniaturized Hair Follicle Density/mm²
Prazo: Day 91 and Day 135

Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.

Day 91 and Day 135
Ratio of Terminal to Miniaturized Hair Follicles
Prazo: Day 91 and Day 135

Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.

Day 91 and Day 135
Beta-catenin in Epidermis and Infundibulum
Prazo: Day 91 and Day 135

Immunohistochemistry of scalp biopsies were used to analyze the nuclear expression outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Percentage of positively-stained nuclei were reported at each timepoint. Change from baseline in percentage of positively-stained nuclei is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.

Day 91 and Day 135
Ki-67 in Epidermis and Infundibulum
Prazo: Day 91 and Day 135

Immunohistochemistry of scalp biopsies were used to analyze the nuclear expression outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Percentage of positively-stained nuclei were reported at each timepoint. Change from baseline in percentage of positively-stained nuclei is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.

Day 91 and Day 135
Ki-67 in Hair Bulb
Prazo: Day 91 and Day 135

Immunohistochemistry of scalp biopsies were used to analyze the nuclear expression outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Percentage of positively-stained nuclei were reported at each timepoint. Change from baseline in percentage of positively-stained nuclei is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91.

Day 91 and Day 135

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Diretor de estudo: Yusuf Yazici, M.D., Biosplice Therapeutics, Inc.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo

1 de agosto de 2015

Conclusão Primária (Real)

1 de abril de 2016

Conclusão do estudo (Real)

1 de abril de 2016

Datas de inscrição no estudo

Enviado pela primeira vez

16 de julho de 2015

Enviado pela primeira vez que atendeu aos critérios de CQ

16 de julho de 2015

Primeira postagem (Estimado)

20 de julho de 2015

Atualizações de registro de estudo

Última Atualização Postada (Real)

1 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

9 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever